Global X Aging Population ETF (AGNG) Valuation
AGNG valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 34.5 trailing earnings
- Forward P/E
- 17.6 analyst estimates
- Price / sales
- 4.49
- Price / book
- 4.74
- EV / EBITDA
- 16.6
- Earnings yield
- 2.90% inverse of P/E
- Dividend yield
- 1.38% of the holdings
- Return on equity
- 13.8% combined
- Net margin
- 13.0% combined
- Beta
- 0.55 weighted, vs S&P 500
AGNG valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| AGNG | 34.5 | 17.6 | 4.49 | 4.74 | 1.38% | 13.8% | 13.0% | 4.7% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
AGNG valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 86.7% | 32.6 | 16.3 | 4.19 | 5.20 | 1.17% | 16.0% |
| Real Estate | 8.6% | 57.1 | 40.0 | 8.96 | 2.96 | 2.78% | 5.2% |
AGNG earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How AGNG weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
AGNG largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 4.00% | 80.6 | 16.4 | 7.8 | 2.42% | 2.74% |
| LLY | Eli Lilly and Company | 3.98% | 42.2 | 24.4 | 14.1 | 0.55% | 5.21% |
| AMGN | Amgen Inc. | 3.55% | 26.9 | 16.7 | 6.1 | 2.33% | 7.31% |
| RO | Roche Holding AG | 3.46% | — | — | — | — | — |
| MRK | Merck & Co., Inc. | 3.36% | 115.8 | 15.3 | 5.4 | 2.33% | 1.60% |
| EW | Edwards Lifesciences Corporation | 3.19% | 51.5 | 25.6 | 7.7 | — | 3.42% |
| WELL | Welltower Inc. | 3.19% | 105.3 | 78.1 | 13.3 | 1.45% | 1.67% |
| JNJ | Johnson & Johnson | 3.12% | 38.8 | 21.0 | 6.2 | 2.10% | 4.44% |
| BMY | Bristol-Myers Squibb Company | 3.09% | 13.2 | 9.4 | 2.5 | 4.22% | 12.99% |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.09% | 19.6 | 14.5 | 5.2 | 0.48% | 8.73% |
| MDT | Medtronic plc | 3.07% | 23.3 | 14.9 | 3.2 | 3.04% | 7.30% |
| 0QIU | Novo Nordisk A/S Class B | 2.98% | — | — | — | — | — |
| VTR | Ventas, Inc. | 2.96% | 159.0 | 128.2 | 6.9 | 2.42% | 1.03% |
| SDZ | Sandoz Group AG | 2.75% | — | — | — | — | — |
| ONC | BeiGene, Ltd. | 2.74% | 66.0 | 35.2 | 6.9 | — | 2.30% |
| SYK | Stryker Corporation | 2.69% | 30.5 | 16.5 | 4.4 | 1.19% | 4.87% |
| AZN | AstraZeneca PLC | 2.44% | — | — | — | — | — |
| 068270 | Celltrion Inc | 2.39% | — | — | — | — | — |
| ALC | Alcon AG | 2.24% | — | — | — | — | — |
| UCB | UCB SA | 2.14% | — | — | — | — | — |
| DXCM | DexCom, Inc. | 2.11% | 34.1 | 28.2 | 6.5 | — | 3.42% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | 2.09% | — | — | — | — | — |
| BSX | Boston Scientific Corporation | 2.03% | 18.0 | 13.2 | 3.1 | — | 6.24% |
| 4503 | Astellas Pharma Inc. | 1.89% | — | — | — | — | — |
| 3692 | Hansoh Pharmaceutical Group Co Ltd | 1.73% | — | — | — | — | — |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About AGNG valuation
Adding up its 42 holdings with company data, AGNG trades at 34.5 times trailing earnings and 17.6 times analysts' forward estimates, with a price-to-book ratio of 4.74 and a dividend yield of 1.38%. Its earnings yield of 2.90% is 2.42 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 34.0% of the fund and earn 55.4% of its combined profit. By sector, Real Estate is the most expensive at 57.1 times earnings and Healthcare the cheapest at 32.6. Companies that lost money over the past year are 4.7% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 61.9% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: AGNG chart, AGNG performance, AGNG holdings, AGNG dividends.
AGNG valuation FAQ
What is the P/E ratio of AGNG?
Based on its holdings, AGNG has a trailing P/E of 34.5 and a forward P/E of 17.6 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of AGNG?
The trailing earnings yield is 2.90% (1 ÷ P/E) and the forward earnings yield 5.69%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is AGNG more expensive than the S&P 500?
AGNG trades at 34.5 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 17.6 and 19.9.
What is the price-to-book ratio of AGNG?
The holdings of AGNG trade at 4.74 times book value, with a combined return on equity of 13.8%.
Which sector in AGNG has the highest P/E?
Real Estate has the highest P/E at 57.1 and Healthcare the lowest at 32.6.